Dr. Calvo earned his Medical Degree in 1993 at the Universidad Autónoma de Madrid in Madrid, Spain and his PhD in 2003 at the Universidad de Navarra in Pamplona, Spain. He trained in Medical Oncology at the Clínica Universitaria de Navarra in Pamplona, Spain and completed his Advanced Fellowship in Drug Development at the Cancer Therapy & Research Center’s Institute for Drug Development in San Antonio, Texas, from 2003 to 2005.
While working in the Medical Oncology Department at the Hospital Vall d’Hebron in Barcelona, Spain, from 2005 to 2008, Dr. Calvo was Co-Director and senior clinical investigator of the Phase I Unit and director of the Genitorurinary Tumors, Sarcoma and CNS Programs.
Dr. Calvo is currently a senior clinical investigator at START Madrid-CIOCC (Centro Integral Oncológico Clara Campal) hospital, in Madrid, Spain, and its director of Clinical Research since its launch in 2008, as well as the President of START Europe. He is also the President and co-founder of the non-profit organization Investigational Therapeutics in Oncological Sciences (INTHEOS) Foundation. In addition, he is Full Professor (Profesor Catedrático) in Oncology and Director of the Oncology PhD/Doctorate Program at Universidad CEU San Pablo in Madrid, Spain
Dr. Calvo is a member of the European Society for Medical Oncology (ESMO) Faculty Group Principles of Clinical Trials and Systemic Therapy. For several years over the past decade, and continuing in some roles today, he has been serving as a member and Track Leader of the Scientific Committee of the ESMO annual meeting, a member of the Scientific Committee of the annual Targeted Agents Therapies (TAT) meeting, and of the Scientific Committee of the annual EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, where he has additionally been appointed as a co-chair.
He has been also co-Director of the ECCO-AACR-EORTC-ESMO International Workshop in Methods in Clinical Cancer Research (2017-2021), the MCCR International Workshop, where he was a Faculty Member during 7 years. Also, Dr. Calvo has been a Track Leader and Committee member for the Scientific Program Committee on the Developmental Therapeutics – Clinical Pharmacology & Experimental Track of the Annual Meetings of the American Society of Clinical Oncology (ASCO), as well as honorary member of the Cancer Education Committee of ASCO. He is a member of the direction committee for the RECIST Working Group, where he co-chairs the iRECIST subcommittee, and serves as a member of the international task force on Methodology for the Development of Innovative Cancer Therapies (MDICT), as well as a Chairman of the Independent Data Monitoring Committee (IDMC) of the EORTC.
Dr. Calvo has co-authored over 170 peer reviewed scientific articles, in addition to multiple chapters in oncology books, as well as several hundreds of international presentations at different major conferences and meetings, especially focusing on clinical development of new drugs in different tumor types. He serves as an ad-hoc reviewer of various oncology journals and has been appointed board editor for different Oncology journals, and is a consultant and reviewer for a variaty of national cancer programs in Europe (Italy, UK, France, Spain). He is a panel expert advisor at multiple Advisory Boards of anticancer drug development and disease-specific cancer therapeutics. During the last 2 decades of full dedication to Clinical Drug development in Oncology, he has participated in around three hundred international studies as a clinical investigator, especially in Early Clinical Drug Development, and, during the last decade, especially focused on novel immunotherapy and targeted agents as antibody-drug conjugates.
